A retrospective analysis of the COLUMBUS cohort found that prolonging azithromycin treatment over more than 1 year did not reduce COPD exacerbations.
The COLUMBUS trial included 92 adults with COPD who had ≥3 exacerbations within the year preceding the trial . Treatment with 500 mg azithromycin or placebo 3 times a week over 12 months resulted in a significantly lower rate of exacerbation with a rate of 0.58 compared with placebo. The new question posed by Dr Sander Talman (Amphia Hospital, the Netherlands) and colleagues was whether continuing the bacteriostatic macrolide azithromycin for longer than 1 year would still entail an efficacious decrease in exacerbations .
The retrospective cohort study assigned the patients from the COLUMBUS investigation to a treatment or a control group, depending on their further therapy with azithromycin during the first year after the trial. Data was analysed for frequency of exacerbations, time to first inc...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Registry Confirms Nintedanib Efficacy under Real-life Conditions Next Article
Predicting Community-acquired Pneumonia Outcomes by microRNA Testing »
Table of Contents: ERS 2019
Holistic View on Asthma
Infectious Respiratory Disease: the Role of Vaccines
Interstitial Lung Disease
Best of the Posters
Novel Developments in Infectious Disease
A New Trial in Pulmonary Vascular Disease
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.